TWOMEY CHRISTOPHER J
Known title: DirectorCIK: 0001238935
Associated companies
Transaction History
| TNDM | ▲ Buy | Option Exercise | 8,759 | $0 | 5/21/2026 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 4,387 | $91K | 5/22/2025 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 4,434 | $229K | 5/24/2024 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 2,757 | $0 | 5/25/2023 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 2,205 | $0 | 5/18/2022 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 238 | $18K | 5/5/2022 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 135 | $10K | 5/5/2022 | View on chart |
| TNDM | ▼ Sell | Open Market | 90 | $10K | 5/5/2022 | View on chart |
| TNDM | ▼ Sell | Open Market | 158 | $18K | 5/5/2022 | View on chart |
| TNDM | ▼ Sell | Gift | 2,500 | $323K | 9/8/2021 | View on chart |
| TNDM | ▼ Sell | Open Market | 304 | $37K | 9/7/2021 | View on chart |
| TNDM | ▼ Sell | Open Market | 4,000 | $460K | 9/2/2021 | View on chart |
| TNDM | ▼ Sell | Open Market | 4,696 | $540K | 9/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Barclays initiates coverage on Tandem Diabetes Care with Equal-Weight rating
Barclays has started covering Tandem Diabetes Care, assigning it an Equal-Weight rating and a price target of $18. This new analyst view comes as the company prepares to discuss its Q2 2026 earnings. The $18 target is at the lower end of the current analyst consensus range, which averages $27.86.
Barclays initiates coverage on Tandem Diabetes Care with Equal-Weight rating. Barclays has started covering Tandem Diabetes Care, assigning it an Equal-Weight rating and a price target of $18. This new analyst view comes as the company prepares to discuss its Q2 2026 earnings. The $18 target is at the lower end of the current analyst consensus range, which averages $27.86.